


Avascular necrosis in SLE / T. Nevskaya et al.





REVIEW

Fig. 4. (supplementary). Funnel plots for prevalence of avascular necrosis (AVN) in patients with systemic lupus erythematosus (SLE): symptomatic AVN (**A**), symptomatic hip AVN (**B**), and asymptomatic AVN (**C**).









OR

0.1

Fig. 5. (supplementary). Funnel plots for the studies reporting risk factors of avascular necrosis (AVN) in patients with systemic lupus erythematosus: Raynaud's phenomenon (A), renal involvement (B), arterial hypertension (C), arthritis (D), serositis (E), central nervous system involvement (F), vasculitis (G), malar skin rash (H), leukopenia (I), thrombocytopenia (J), IgG anticardiolipin antibodies (K), cumulative dose of corticosteroids (L), pulse therapy (M), use of immunosuppressive drugs (N), use of antimalarial drugs (O), age at SLE diagnosis (P), disease duration (Q), disease activity assessed with SLEDAI (R), mean daily dose of corticosteroids (S), the highest daily dose of corticosteroids (T), duration of corticosteroid therapy (U), and anti-ds DNA (V).